Barclays’s Coherus Oncology CHRS Stock Holding History

Barclays’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-49,900	Closed	-$119K	–	4920
2024 Q1	$119K	Buy	+49,900	New	+$123K	﹤0.01%	4369
2020 Q1	–	Sell	-100	Closed	-$2K	–	6162
2019 Q4	$2K	Buy	+100	New	+$1.84K	﹤0.01%	6236
2019 Q2	–	Sell	-5,300	Closed	-$72K	–	6960
2019 Q1	$72K	Buy	5,300 +300	+6%	+$4K	﹤0.01%	5615
2018 Q4	$45K	Buy	+5,000	New	+$57.9K	﹤0.01%	5525
2018 Q2	–	Sell	-100	Closed	-$1K	–	6992
2018 Q1	$1K	Sell	100 -300	-75%	-$3.28K	﹤0.01%	6946
2017 Q4	$4K	Buy	+400	New	+$4.28K	﹤0.01%	6686

Other funds holding CHRS

TGY2IT

Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Barclays's CHRS Position: Q2 2026 in Review

Barclays increased its Coherus Oncology (CHRS) stake by 2.9% in Q2 2026, buying an estimated $9.26K and bringing the position to 201,143 shares worth $282K. The position accounts for ﹤0.01% of the portfolio, ranked #3525.

Barclays first reported a position in CHRS in Q4 2014 and has held it in 47 quarters since. The position peaked at $11.6M in Q4 2023. 147 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

Barclays held 201,143 shares of Coherus Oncology worth $282K as of Q2 2026.
Barclays bought 5,670 Coherus Oncology shares in Q2 2026, an estimated $9.26K.
Coherus Oncology made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3525 holding.
Barclays first reported a position in Coherus Oncology in Q4 2014 and has held it in 47 quarters since.
Barclays's Coherus Oncology position peaked at $11.6M in Q4 2023.
147 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.